candesartan has been researched along with Carotid Stenosis in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Carotid Stenosis: Narrowing or stricture of any part of the CAROTID ARTERIES, most often due to atherosclerotic plaque formation. Ulcerations may form in atherosclerotic plaques and induce THROMBUS formation. Platelet or cholesterol emboli may arise from stenotic carotid lesions and induce a TRANSIENT ISCHEMIC ATTACK; CEREBROVASCULAR ACCIDENT; or temporary blindness (AMAUROSIS FUGAX). (From Adams et al., Principles of Neurology, 6th ed, pp 822-3)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Scandinavian Candesartan Acute Stroke Trial (SCAST) showed no beneficial clinical effects of blood pressure lowering with the angiotensin receptor blocker candesartan in the acute phase of stroke." | 5.20 | Effects of blood pressure lowering in patients with acute ischemic stroke and carotid artery stenosis. ( Bath, PM; Berge, E; Jusufovic, M; Karlson, BW; Sandset, EC, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jusufovic, M | 1 |
| Sandset, EC | 1 |
| Bath, PM | 1 |
| Karlson, BW | 1 |
| Berge, E | 1 |
1 trial available for candesartan and Carotid Stenosis
| Article | Year |
|---|---|
Effects of blood pressure lowering in patients with acute ischemic stroke and carotid artery stenosis.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2015 |